When Canada chose an adjuvanted influenza A H1N12009 vaccine for pandemic control, dosing requirements and safety in children were unknown. This study compared responses after 1 and 2 doses in young children.
Five Canadian centers evaluated ASO3-adjuvanted H1N12009 vaccine (Arepanrix, GSK Laval, Quebec) in children aged 6 to 35 months, given 2 doses (0.25 mL, 1.9 μg hemagglutinin) 21 days apart. Blood was collected at baseline and 21 to 28 days after each dose to measure hemagglutination inhibition antibody titers. Adverse events were documented daily for 7 days after each dose.
Centers enrolled 167 children (mean age, 19 months). At baseline, 29 children (17.4%) had hemagglutination inhibition titers ≥10. After dose 1, titers ≥40 were present in 79.7% of initially naive subjects and 100% of initially primed subjects, whose respective geometric mean titers were 68 and 1020 (P < 0.001). After dose 2, 100% of subjects had titers ≥40, with geometric mean titers increasing to 723 in naive subjects and to 1854 in primed subjects (P < 0.001). Injection site reactions occurred in 56% of subjects after dose 1 and 43% after dose 2 (P < 0.01), with severe reactions noted in ≤3%. Fever >39.0°C was infrequent after either dose (5.4%, 6.6%, P = 0.20). Mild or moderate general symptoms were common but short-lived and less frequent after dose 2.
One dose of adjuvanted vaccine met criteria for licensing seasonal influenza vaccines. A second dose increased titers substantially, potentially affording greater or more durable protection. Adverse effects were common but tolerable. The use of adjuvanted seasonal influenza vaccines in young children merits consideration.
From the *Vaccine Evaluation Center, BC Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada; †Vaccine Study Center, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada; ‡Unité de Recherche en Santé Publique (CHUQ) and Laval University, Québec City, Quebec, Canada; §ACHIEVE Research Team, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; ¶Canadian Center for Vaccinology, Dalhousie University, IWK Health Center and Capital Health District Authority, Halifax, Nova Scotia, Canada; ∥Virology Section, National Microbiology Laboratory, Winnipeg, Manitoba, Canada; and **Vaccine Safety Section, Public Health Agency of Canada, Ottawa, Ontario, Canada.
Accepted for publication November 10, 2010.
Supported by a grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research, Ottawa, Canada.
Address for correspondence: David Scheifele, MD, Child and Family Research Institute (A5–174), 950 West 28th Ave, Vancouver, British Columbia, Canada, V5Z 4H4. E-mail: email@example.com.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.pidj.com).